| Not Yet Recruiting | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Me NCT07492680 | Bristol-Myers Squibb | Phase 2 |
| Not Yet Recruiting | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors NCT07297160 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated NCT07176975 | Boehringer Ingelheim | Phase 1 |
| Not Yet Recruiting | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 | Mirati Therapeutics Inc. | Phase 2 |
| Not Yet Recruiting | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors NCT07537881 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain M NCT07178938 | MedSIR | Phase 2 |
| Not Yet Recruiting | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cance NCT07509034 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors NCT07529002 | Peking University Cancer Hospital & Institute | — |
| Recruiting | A Study of GEN1106 in Participants With Solid Tumors NCT07416123 | Genmab | Phase 1 |
| Recruiting | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metasta NCT07522073 | Incyte Corporation | Phase 3 |
| Recruiting | A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People Wi NCT07395258 | Boehringer Ingelheim | Phase 1 |
| Not Yet Recruiting | Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification NCT07417501 | Tongji Hospital | Phase 2 |
| Recruiting | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors NCT07374848 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Recruiting | Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors NCT07505069 | Nanolattix Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant S NCT07385950 | Zhongnan Hospital | — |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tu NCT07279428 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916 | Incyte Corporation | Phase 1 |
| Not Yet Recruiting | First in Human Study of QLS5316 in Solid Tumors NCT07358884 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | DPTX3186 in Wnt Pathway Activated Solid Tumors NCT07312903 | Dewpoint Therapeutics | Phase 1 |
| Recruiting | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors NCT07035249 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Canc NCT07274852 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Sol NCT07407985 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Not Yet Recruiting | Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors NCT06933524 | Autotelicbio | Phase 1 |
| Recruiting | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors NCT07231211 | Shanghai Shengdi Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of HDM2017 in Advanced Solid Tumors NCT07274085 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors NCT07232407 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors NCT07265622 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Adv NCT07181681 | BeOne Medicines | Phase 1 |
| Recruiting | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment NCT07351903 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Recruiting | Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors NCT07231081 | Tcelltech Inc. | Phase 1 |
| Recruiting | A Study of DS3610a in Participants With Advanced Solid Tumor NCT07159126 | Daiichi Sankyo | Phase 1 |
| Completed | G-CSF-Induced Bone Pain and Supportive Care Approaches NCT07192770 | Ankara Etlik City Hospital | — |
| Not Yet Recruiting | Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens NCT07128576 | Zhujiang Hospital | Phase 2 |
| Recruiting | Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors NCT07152236 | Guangzhou Bio-gene Technology Co., Ltd | N/A |
| Recruiting | A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors NCT06973863 | PharmaEngine | Phase 1 |
| Recruiting | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors NCT07123103 | Exelixis | Phase 1 |
| Recruiting | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors NCT07105215 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors NCT07158918 | ABL Bio, Inc. | Phase 1 / Phase 2 |
| Recruiting | PumaRx Registry Trial NCT06805461 | RenovoRx | — |
| Recruiting | A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors NCT07055594 | Shine-On Biomedical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors NCT06953089 | DualityBio Inc. | Phase 2 |
| Recruiting | A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors NCT07032077 | Shandong Suncadia Medicine Co., Ltd. | Phase 2 |
| Recruiting | Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors NCT06651593 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients NCT07043894 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Active Not Recruiting | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors NCT06873789 | Incyte Corporation | Phase 1 / Phase 2 |
| Recruiting | Study of AUBE00 in Patients With Solid Tumors NCT07030959 | Chugai Pharmaceutical | Phase 1 |
| Not Yet Recruiting | An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory So NCT06951425 | Shanghai Tongji Hospital, Tongji University School of Medicine | EARLY_Phase 1 |
| Recruiting | Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 NCT06410131 | Sound Biopharmaceuticals Ltd. | Phase 1 |
| Recruiting | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer NCT06736379 | VLP Therapeutics | Phase 1 |
| Recruiting | A Study of ZL-1310 in Participants With Selected Solid Tumors NCT06885281 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity NCT07018622 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 |
| Not Yet Recruiting | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors NCT06955390 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Terminated | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors NCT06799533 | Pfizer | Phase 1 |
| Not Yet Recruiting | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. NCT06928363 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors NCT06963281 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 1 |
| Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tu NCT06915753 | Tyra Biosciences, Inc | Phase 1 |
| Not Yet Recruiting | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid NCT06926751 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Evaluation of SYS6005 in Patients With Advanced Malignant Tumor NCT06958679 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 |
| Not Yet Recruiting | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors NCT06947226 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutatio NCT06818812 | Incyte Corporation | Phase 1 |
| Recruiting | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors NCT06826313 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Meta NCT06809530 | Guangzhou Medical University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer NCT06762327 | Nanjing First Hospital, Nanjing Medical University | Phase 2 |
| Recruiting | ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC NCT06816992 | ORIC Pharmaceuticals | Phase 1 |
| Recruiting | A Study of HS-20110 in Participants With Advanced Solid Tumors NCT06892379 | Hansoh BioMedical R&D Company | Phase 1 |
| Completed | A Study of AL8326 in Healthy Subjects NCT07132957 | Advenchen Laboratories Nanjing Ltd. | Phase 1 |
| Not Yet Recruiting | A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Rel NCT06761417 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Enrolling By Invitation | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product NCT06925685 | Allogene Therapeutics | — |
| Recruiting | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) NCT06710132 | EMD Serono Research & Development Institute, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of SHR-4375 in Subjects With Solid Tumors NCT06764628 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors NCT06755086 | Peking University Cancer Hospital & Institute | — |
| Recruiting | A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors NCT06783569 | JiaRay Group | Phase 1 |
| Recruiting | A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors NCT06710379 | Adcentrx Therapeutics | Phase 1 |
| Active Not Recruiting | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors NCT06806046 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Recruiting | Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors NCT06727812 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 |
| Recruiting | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors NCT06621563 | Hansoh BioMedical R&D Company | Phase 1 |
| Withdrawn | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with NCT06331598 | Hoffmann-La Roche | Phase 2 |
| Recruiting | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors NCT06644755 | Daiichi Sankyo | Phase 1 |
| Recruiting | A Phase 2 Clinical Study of ABSK061 and ABSK043 NCT06632262 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Recruiting | A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumor NCT06873555 | Heronova Pharmaceuticals | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors NCT06992687 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy NCT06553157 | Minia University | Phase 1 / Phase 2 |
| Completed | A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given A NCT06345001 | Bayer | Phase 1 |
| Not Yet Recruiting | A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors NCT06553846 | Fudan University | Phase 1 |
| Completed | Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi) NCT06296056 | Seoul Hospital | Phase 1 |
| Recruiting | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation NCT06386146 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injecti NCT06431594 | GlaxoSmithKline | Phase 1 |
| Recruiting | Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation NCT06536400 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other NCT06390995 | Takeda | Phase 1 / Phase 2 |
| Not Yet Recruiting | Spatial Profile of Tumors NCT06298773 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Personalized Neoantigen Peptide Vaccines for Solid Tumors NCT07002203 | Seqker Biosciences, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Part NCT05644626 | BeiGene | Phase 1 |
| Terminated | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and NCT06158958 | AbbVie | Phase 1 |
| Recruiting | QTX3034 in Patients With KRAS G12D Mutation NCT06227377 | Quanta Therapeutics | Phase 1 |
| Withdrawn | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast C NCT05905341 | Pfizer | Phase 1 |
| Recruiting | Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimm NCT07249060 | Hospital Universitario Araba | — |
| Recruiting | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutatio NCT06179160 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors NCT06205706 | BioInvent International AB | Phase 1 / Phase 2 |
| Terminated | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or NCT05976334 | Takeda | Phase 1 |
| Active Not Recruiting | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Ad NCT06049212 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cell NCT06066424 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors NCT06082960 | Gilead Sciences | Phase 1 |
| Active Not Recruiting | A Study of ADRX-0706 in Select Advanced Solid Tumors NCT06036121 | Adcentrx Therapeutics | Phase 1 |
| Unknown | Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors NCT06001684 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home NCT06163053 | Bristol-Myers Squibb | — |
| Unknown | A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advance NCT06011291 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Terminated | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors NCT05996445 | Xencor, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 | Incyte Corporation | Phase 1 |
| Recruiting | CTS2190 Phase I /II Clinical Study in Patients NCT06224387 | CytosinLab Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer NCT05839600 | Boehringer Ingelheim | Phase 1 |
| Enrolling By Invitation | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenviron NCT05600933 | National Cancer Institute (NCI) | — |
| Completed | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors NCT05731947 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With NCT05471856 | Boehringer Ingelheim | Phase 1 |
| Recruiting | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797 | Fore Biotherapeutics | Phase 2 |
| Recruiting | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Soli NCT05650242 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Completed | A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body NCT05613036 | Boehringer Ingelheim | Phase 1 |
| Unknown | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer NCT05904457 | Asan Medical Center | Phase 2 |
| Recruiting | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors NCT05490472 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, P NCT05512377 | Boehringer Ingelheim | Phase 2 |
| Completed | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combi NCT05668585 | C4 Therapeutics, Inc. | Phase 1 |
| Unknown | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors NCT05648994 | Fujian Cancer Hospital | EARLY_Phase 1 |
| Withdrawn | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors NCT04791228 | Children's National Research Institute | Phase 2 |
| Recruiting | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors NCT05536141 | Arcus Biosciences, Inc. | Phase 1 |
| Unknown | 6MW3511 in Patients With Advanced Solid Tumor NCT05524194 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpres NCT05325866 | Amgen | Phase 1 / Phase 2 |
| Withdrawn | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch NCT05419817 | Haider Mahdi | Phase 2 |
| Completed | A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by T NCT05372367 | Boehringer Ingelheim | Phase 1 |
| Suspended | A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT05416749 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Screening Study for Participants With Malignant Tumors NCT05419375 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors NCT06873542 | Heronova Pharmaceuticals | Phase 1 |
| Recruiting | Study of INCB123667 in Subjects With Advanced Solid Tumors NCT05238922 | Incyte Corporation | Phase 1 |
| Recruiting | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Particip NCT05203172 | Pfizer | Phase 4 |
| Recruiting | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumor NCT07016997 | Chiome Bioscience Inc. | Phase 1 |
| Recruiting | A Study of ZG005 in Patients With Advanced Solid Tumors NCT06233292 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors NCT05216965 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid NCT05101070 | Shionogi | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tu NCT05740215 | Shandong New Time Pharmaceutical Co., LTD | Phase 1 / Phase 2 |
| Completed | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphoc NCT05225584 | Kymera Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination W NCT05327946 | Boehringer Ingelheim | Phase 1 |
| Terminated | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tu NCT05387265 | CytomX Therapeutics | Phase 1 |
| Withdrawn | Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors NCT05231733 | SparX Biotech(Jiangsu) Co., Ltd. | Phase 1 |
| Recruiting | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People Wi NCT05155332 | Boehringer Ingelheim | Phase 1 |
| Active Not Recruiting | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants NCT05262400 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration NCT05315700 | ORIC Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants NCT05129280 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of TAK-103 in Adult With Solid Tumors NCT05164666 | Takeda | Phase 1 |
| Active Not Recruiting | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study NCT05167071 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 1 |
| Terminated | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants NCT04939701 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab i NCT05149027 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 1 |
| Completed | Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors NCT04261413 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | Phase 1 |
| Active Not Recruiting | Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors NCT05522582 | Yancheng First People's Hospital | Phase 2 |
| Recruiting | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors NCT05024214 | 3D Medicines (Sichuan) Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Recruiting | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Sol NCT04337177 | Valent Technologies, LLC | Phase 1 |
| Active Not Recruiting | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are NCT05059522 | Pfizer | Phase 3 |
| Unknown | A Phase 1b Study of ZN-c3 in Chinese Subjects NCT04972422 | Zentera Therapeutics HK Limited | Phase 1 |
| Unknown | Microtransplantation for Advanced and Relapsed Solid Tumors NCT04937842 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 1 / Phase 2 |
| Terminated | IBI188 Combination Therapy in Solid Tumors NCT04861948 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumo NCT04570423 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combi NCT04857138 | Hoffmann-La Roche | Phase 1 |
| Completed | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors NCT04774952 | Revolution Medicines, Inc. | Phase 1 |
| Completed | A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors NCT04730843 | Elpiscience Biopharma, Ltd. | Phase 1 |
| Unknown | Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Tori NCT04727164 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 1 |
| Completed | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it NCT04704154 | Bayer | Phase 2 |
| Terminated | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 NCT04674748 | Incyte Biosciences Japan GK | Phase 1 |
| Active Not Recruiting | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study NCT04589845 | Hoffmann-La Roche | Phase 2 |
| Terminated | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants NCT04642365 | Hoffmann-La Roche | Phase 1 |
| Completed | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study NCT04672460 | Pfizer | Phase 1 |
| Completed | A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With NCT04653142 | Boehringer Ingelheim | Phase 1 |
| Terminated | A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors NCT04613492 | AstraZeneca | Phase 1 |
| Completed | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors NCT04627740 | Xinqiao Hospital of Chongqing | Phase 1 / Phase 2 |
| Completed | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX- NCT04574583 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Mobile Sensor Technologies to Assess General Symptomology of People With Cancer NCT04465214 | National Cancer Institute (NCI) | — |
| Completed | A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Met NCT04341259 | Hoffmann-La Roche | Phase 1 |
| Completed | Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Ca NCT04442425 | National Cancer Institute (NCI) | — |
| Recruiting | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors NCT04685226 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants Wit NCT04260009 | Takeda | Phase 1 / Phase 2 |
| Unknown | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China NCT03998345 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | N/A |
| Completed | A Study of DF6002 Alone and in Combination With Nivolumab NCT04423029 | Dragonfly Therapeutics | Phase 1 |
| Terminated | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors NCT04405778 | Takeda | Phase 1 |
| Suspended | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutatio NCT04418167 | JS InnoPharm, LLC | Phase 1 |
| Recruiting | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tum NCT06636435 | Chiome Bioscience Inc. | Phase 1 |
| Completed | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With NCT04303858 | Hoffmann-La Roche | Phase 1 |
| Completed | MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. NCT05877651 | HRYZ Biotech Co. | Phase 1 |
| Unknown | A Study of RC98 in Subjects With Advanced Malignant Solid Tumors NCT04190823 | RemeGen Co., Ltd. | Phase 1 |
| Active Not Recruiting | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizum NCT04250155 | Genentech, Inc. | Phase 1 |
| Terminated | KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors NCT04237649 | Novartis Pharmaceuticals | EARLY_Phase 1 |
| Recruiting | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or So NCT03934372 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Terminated | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combi NCT04029688 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Bo NCT04187456 | AstraZeneca | Phase 1 |
| Terminated | A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors NCT04158583 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombi NCT04123366 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumo NCT04140500 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) NCT04174716 | Idience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combi NCT04118842 | AstraZeneca | Phase 1 |
| Completed | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors NCT03954067 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Terminated | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors NCT04009460 | Elpiscience Biopharma, Ltd. | Phase 1 |
| Completed | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors NCT03965845 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Terminated | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sp NCT03926143 | Bayer | Phase 2 |
| Active Not Recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 | Pfizer | Phase 2 |
| Terminated | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced NCT03861403 | Leap Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | GEN1046 Safety Trial in Patients With Malignant Solid Tumors NCT03917381 | Genmab | Phase 1 / Phase 2 |
| Completed | A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid T NCT03946800 | MedImmune LLC | Phase 1 |
| Unknown | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A NCT03950297 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Active Not Recruiting | Avelumab Program Rollover Study NCT03815643 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Completed | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) NCT03745989 | Merck Sharp & Dohme LLC | Phase 1 |
| Active Not Recruiting | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors NCT03832569 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors NCT03813615 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participan NCT03762447 | Incyte Corporation | Phase 1 |
| Withdrawn | Study of CD133KDEL Toxin in the Treatment for Solid Tumors NCT02845414 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Study of Avelumab-M3814 Combinations NCT03724890 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors NCT03366116 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Biomarkers for Prediction of Tumor Response to Radiotherapy NCT03744819 | Chuangzhen Chen | — |
| Completed | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With A NCT03708328 | Hoffmann-La Roche | Phase 1 |
| Unknown | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors NCT03634982 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treat NCT03486873 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Compara NCT03477175 | Eisai Inc. | Phase 2 |
| Completed | Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy NCT03616834 | Effector Therapeutics | Phase 2 |
| Terminated | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML NCT03690154 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 |
| Terminated | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors NCT03539484 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT03448042 | Genentech, Inc. | Phase 1 |
| Unknown | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors NCT03503604 | SuZhou Stainwei Biotech Inc. | Phase 1 |
| Completed | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Se NCT03473925 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Met NCT03347123 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan NCT03255070 | Ambrx, Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or W NCT03361228 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Study of E7130 in Participants With Solid Tumors NCT03444701 | Eisai Co., Ltd. | Phase 1 |
| Withdrawn | Prospective Patient Registry for Radiation Oncology Techniques and Quality NCT02368106 | University of Maryland, Baltimore | — |
| Terminated | Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanc NCT03301896 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors NCT03386942 | Eisai Inc. | Phase 1 |
| Completed | A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants NCT03362723 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tum NCT03264066 | Hoffmann-La Roche | Phase 2 |
| Completed | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors NCT03314935 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pha NCT03313557 | AstraZeneca | Phase 1 |
| Recruiting | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid NCT03175224 | Apollomics Inc. | Phase 2 |
| Unknown | Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patie NCT03258151 | Cui Yimin | — |
| Terminated | M3541 in Combination With Radiotherapy in Solid Tumors NCT03225105 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Completed | A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volu NCT03258515 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors NCT03252938 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 1 |
| Active Not Recruiting | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumo NCT03313778 | ModernaTX, Inc. | Phase 1 |
| Terminated | Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors NCT02587962 | Medivir | Phase 1 / Phase 2 |
| Completed | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) NCT03235570 | Incyte Corporation | Phase 1 |
| Terminated | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma a NCT03144661 | Incyte Corporation | Phase 1 |
| Completed | Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors NCT03101488 | 3D Medicines (Sichuan) Co., Ltd. | Phase 1 |
| Completed | Ceramide NanoLiposome in Patients With Advanced Solid Tumors NCT02834611 | Keystone Nano, Inc | Phase 1 |
| Completed | Study of Ixazomib and Erlotinib in Solid Tumors NCT02942095 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer NCT02216669 | Maastricht Radiation Oncology | Phase 1 |
| Suspended | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib NCT03065062 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas NCT03030417 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) NCT02959437 | Incyte Corporation | Phase 1 / Phase 2 |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Completed | Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms NCT03006029 | Theramab LLC | Phase 1 |
| Completed | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advan NCT03010176 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors NCT02827968 | 3D Medicines (Sichuan) Co., Ltd. | Phase 1 |
| Completed | Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors NCT03006887 | Eisai Co., Ltd. | Phase 1 |
| Completed | ODM-207 in Patients With Advance Solid Tumours NCT03035591 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Terminated | Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies NCT02620839 | Pamela Munster | Phase 1 |
| Unknown | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers NCT02797795 | Neovia Oncology Ltd. | Phase 1 |
| Completed | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors NCT02988817 | Genmab | Phase 1 / Phase 2 |
| Withdrawn | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors NCT02674555 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Kanitinib in Treating Patients With Advanced Solid Tumors NCT02916095 | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contracept NCT02705963 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors NCT02789228 | Children's National Research Institute | Phase 1 |
| Terminated | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183 | AeRang Kim | Phase 1 |
| Completed | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452 | Syndax Pharmaceuticals | Phase 1 |
| Completed | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients NCT02903914 | Incyte Corporation | Phase 1 |
| Completed | A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of NCT02828930 | Hoffmann-La Roche | Phase 1 |
| Terminated | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis NCT02890368 | Pfizer | Phase 1 |
| Completed | A Phase I Trial of HS-10241 in Solid Tumors NCT02759640 | Atridia Pty Ltd. | Phase 1 |
| Completed | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778 | Syndax Pharmaceuticals | Phase 1 |
| Unknown | MASCT-I Treatment for Advanced Solid Tumor NCT02858232 | The First People's Hospital of Lianyungang | Phase 1 / Phase 2 |
| Completed | A Study of ERY974 in Patient With Advanced Solid Tumors NCT02748837 | Chugai Pharmaceutical | Phase 1 |
| Completed | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lym NCT02740270 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With NCT02761694 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 |
| Terminated | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) NCT02702492 | Karyopharm Therapeutics Inc | Phase 1 |
| Completed | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors NCT02759666 | Atridia Pty Ltd. | Phase 1 |
| Completed | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors NCT02746081 | Bayer | Phase 1 |
| Completed | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumo NCT02762981 | Corcept Therapeutics | Phase 1 / Phase 2 |
| Completed | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated S NCT02639546 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies NCT02711137 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer NCT02632448 | Esperas Pharma Inc. | Phase 1 / Phase 2 |
| Completed | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Bre NCT02719691 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Prima NCT02650401 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes NCT02680795 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies NCT02721043 | Nina Bhardwaj | Phase 1 |
| Withdrawn | Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) NCT02766842 | Johns Hopkins University | Phase 2 |
| Completed | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors NCT02699515 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Terminated | A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases NCT02700308 | Centre Leon Berard | Phase 2 |
| Completed | A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors NCT02881138 | RemeGen Co., Ltd. | Phase 1 |
| Completed | Study of JS001 in Participants With Advanced Solid Tumors NCT02857166 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Terminated | A Study of PLX51107 in Advanced Malignancies NCT02683395 | Plexxikon | Phase 1 |
| Completed | A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors NCT02667873 | Stemline Therapeutics, Inc. | Phase 1 |
| Completed | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer NCT02546531 | Washington University School of Medicine | Phase 1 |
| Completed | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants Wi NCT02660034 | BeiGene | Phase 1 |
| Terminated | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor NCT02673736 | Plexxikon | Phase 1 |
| Unknown | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Su NCT02675946 | Curegenix Inc. | Phase 1 |
| Completed | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced NCT02646748 | Incyte Corporation | Phase 1 |
| Completed | A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizuma NCT02650713 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated NCT02593786 | Bristol-Myers Squibb | Phase 1 / Phase 2 |